series-c-plus
Stage
1
Investors
About
Aviceda develops novel glyco-immune checkpoint therapeutics targeting immune-mediated diseases, with a lead program focused on treating macular degeneration.
Explore Aviceda's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.